Wednesday, February 10, 2010, 1:28PM AEST - The Australian Stockmarket closes in 2 hours and 37 minutes.
To create a watchlist or portfolio of shares, Register

Xenoport, Inc. (XNPT)

8:00AM AEST: 18.92 USD  Down 0.20 (1.05%)  
 MORE ON XNPT 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 XenoPort, Inc. (NasdaqNM:XNPT) Delayed quote dataEdit
Last Trade:18.92 USD
Trade Time: 8:00AM AEST
Change:Down 0.20 (1.05%)
Prev Close:19.12
Open:19.29
Bid:18.85 x 100
Ask:21.61 x 1000
1y Target Est:31.31
Day's Range:18.81 - 19.36
52wk Range:13.36 - 27.37
Volume:201,690
Avg Vol (3m):324,492
Market Cap:574.03M
P/E (ttm):N/A
EPS (ttm):-2.43
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add XNPT to Portfolio   Download Data

 HEADLINES 
InPlay: XenoPort announces extension of the Horizant PDUFA date to February 11, 2010
Briefing.com (Wed 8:13AM)
XenoPort Announces Extension of the Horizant PDUFA Date to February 11, 2010
Business Wire (Wed 8:13AM)
Glaxo savings plan may hit XenoPort partnership
AP (Fri, Feb 5)
XenoPort Announces Horizant as Brand Name for XP13512
Business Wire (Fri, Feb 5)
Biotech Calendar: Key Dates for February
at TheStreet.com (Tue, Feb 2)
XENOPORT INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
EDGAR Online (Wed, Jan 20)
XenoPort to Present at the 28th Annual J.P. Morgan Healthcare Conference
Business Wire (Sat, Jan 9)
XENOPORT INC Files SEC form 8-K, Other Events
EDGAR Online (Fri, Nov 20)
Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
Business Wire (Thu, Nov 19)
Music to Health-Care Investors' Ears
at Motley Fool (Tue, Nov 17)
More Headlines for XNPT...

 ANALYST 
EPS Est (next year) (Dec-09) :-2.41
EPS Est (in 2 years) (Dec-10) :-2.29
Avg Rec (current)*:2.1
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
XenoPort, Inc., a biopharmaceutical company, focuses on developing internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices